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Purpose: To facilitate future diagnosis of Knobloch syndrome (KS) and better understand its etiology, we sought to
identify not yet described COL18A1 mutations in KS patients. In addition, we tested whether mutations in this gene lead
to absence of the COL18A1 gene product and attempted to better characterize the functional effect of a previously reported
missense mutation.
Methods: Direct sequencing of COL18A1 exons was performed in KS patients from four unrelated pedigrees. We used
immunofluorescent histochemistry in skin biopsies to evaluate the presence of type XVIII collagen in four KS patients
carrying two already described mutations: c.3277C>T, a nonsense mutation, and c.3601G>A, a missense mutation.
Furthermore,  we  determined  the  binding  properties  of  the  mutated  endostatin  domain  p.A1381T  (c.3601G>A)  to
extracellular matrix proteins using ELISA and surface plasmon resonance assays.
Results: We identified four novel mutations in COL18A1, including a large deletion involving exon 41. Skin biopsies
from KS patients revealed lack of type XVIII collagen in epithelial basement membranes and blood vessels. We also found
a reduced affinity of p.A1381T endostatin to some extracellular matrix components.
Conclusions: COL18A1 mutations involved in Knobloch syndrome have a distribution bias toward the coding exons of
the C-terminal end. Large deletions must also be considered when point mutations are not identified in patients with
characteristic KS phenotype. We report, for the first time, lack of type XVIII collagen in KS patients by immunofluorescent
histochemistry in skin biopsy samples. As a final point, we suggest the employment of this technique as a preliminary
and complementary test for diagnosis of KS in cases when mutation screening either does not detect mutations or reveals
mutations of uncertain effect, such as the p.A1381T change.
Knobloch  syndrome  (KS;  OMIM  267750)  is  an
autosomal recessive disorder characterized by high myopia,
macular  abnormalities,  vitreoretinal  degeneration,  retinal
detachment, and occipital encephalocele [1-4]. The spectrum
of clinical variability is not completely known due to the small
number of cases reported in the literature [5]. Most KS cases
are  caused  by  null  mutations  in  the  COL18A1  gene
(chr21q22.3), which comprises 43 exons and transcribes three
different isoforms by the use of two promoters and alternative
splicing in the third exon [4,6]. The three encoded collagen
XVIII proteins differ only by their signal peptides and by part
of the N-terminal region of the NC11 domain. The short
isoform (NC11–303) is transcribed from the first promoter,
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upstream of exon 1, and is encoded by exons 1, 2, 4–43. The
intermediate (NC11–493) and long (NC11–728) forms are
transcribed from the second promoter, upstream of exon 3,
and they differ by use of an internal splice site within exon 3.
Collagen XVIII is a component of basement membranes [7];
however,  the  abundance  of  its  isoforms  varies:  the  short
isoform  is  predominant  in  most  tissues,  including  heart,
kidney, retina, and fetal brain, while the intermediate and long
isoforms are highly expressed in the liver [3,4,6]. The C-
terminal domain of type XVIII collagen can be cleaved to
form endostatin, which functions as a potent angiogenesis
inhibitor  that  influences  endothelial  cell  proliferation,
migration,  apoptosis  and  tubulogenesis  [8-11].  Endostatin
binds  to  several  extracellular  matrix  (ECM)  components,
including laminin-1, fibulin-1, fibulin-2, nidogen-2, perlecan,
heparan sulfate, and fibronectin [12-14].
To date, 12 rare mutations have been described in KS
patients with the typical clinical features of the disease [3-5,
15-17].  All  mutations,  with  the  exception  of  a  missense
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801change (p.A1381T; numbered according to GenBank cDNA
AF018081.1) of still unclear functional effect on the protein
[18,19], are predicted to create premature stop codons. These
mutations possibly lead to a lack of the protein, even though
the  complete  lack  of  collagen  XVIII  has  still  not  been
demonstrated. COL18A1 mutations are distributed along the
gene in regions common to all known isoforms, except for c.
12–2A>T,  which  only  affects  the  short  isoform.  The
description of pathogenic mutations in a larger number of KS
patients  and  further  functional  analysis  of  the  mutation
p.A1381T may better characterize the spectrum of mutations
along the COL18A1 gene.
Screening  the  entire  gene  for  mutations  is  still  time
consuming. We have previously shown that endostatin plasma
measurements do not allow a precise diagnosis, as patients
with null mutations had positive levels of this fragment [4],
and no other methods to confirm KS diagnosis were tested.
New strategies that might allow the screening of a larger
number of patients, including those without the full phenotype
of the syndrome, could help delineate the clinical variability.
In the present work we describe four new families with
KS  patients  and  the  respective  responsible  mutations  in
COL18A1.  Consistent  with  previous  results,  we  find
heterogeneity for mutation sites leading to this syndrome. We
also assessed the immunohistochemical expression of type
XVIII  collagen  in  skin  biopsies  of  KS  patients  carrying
nonsense mutations to test the potential of this method as a
screening tool for a larger number of patients. Finally, we
evaluated in situ and in vitro effects of endostatin p.A1381T
by  testing  skin  biopsies  for  the  presence  of  type  XVIII
collagen in KS patients carrying this mutation and evaluating
the binding properties of the mutated endostatin to other ECM
components.
METHODS
COL18A1 mutations analysis: Five KS patients were referred
to  the  Centro  de  Estudos  do  Genoma  Humano  at  the
University of São Paulo. Two were siblings and the other three
were not related. They presented with typical KS phenotypic
characteristics:  high  myopia  detected  early  in  childhood
(usually before 1 year of age) and occipital encephalocele, as
described  elsewhere  [2,20].  No  other  alterations  were
observed.
We screened for mutations in the COL18A1 gene by
direct sequencing of exons and flanking intronic regions, as
previously described [4]. All mutations were named according
to  the  nomenclature  suggested  by  den  Dunnen  and
Antonarakis [21]. The numbering followed the short isoform
(GenBank AF018082.1), except where indicated.
Skin biopsies: After informed consent was obtained, 5 mm
skin punch biopsies were taken from the forearms of four other
KS patients, who were from two unrelated families. Clinical
and molecular analysis of these patients has been described in
detail by Suzuki et al. and Kliemann et al. [4,18]. Control skin
samples  were  obtained  from  two  patients  that  were
undergoing surgery and had no suspicion of KS. Informed
consent was also obtained from these patients. This project
was approved by the Ethical Committee of the Institute of
Biosciences, University of São Paulo (São Paulo, Brazil).
Tissue  samples  were  fixed  according  to  a  procedure
described elsewhere [22]. Briefly, samples were immediately
fixed  and  cryosubstituted  in  a  −70  °C  solution  of  80%
methanol  and  20%  dimethyl  sulfoxide  for  5–7  days,
transferred to −20 °C for 1–2 days, and then brought to room
temperature. Samples were rinsed 3X in absolute ethanol and
embedded in Paraplast Plus following standard protocols. In
addition to maintaining morphological structure, this method
also appears to preserve the antigenicity to a higher degree
than aldehyde fixatives.
Immunofluorescent  histochemistry:  Xylene  was  used  to
dewax  7  μm-thick  sections.  These  were  then  rehydrated
through a graded series of ethanol into phosphate-buffered
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2  mM  KH2PO4,  pH  7.4).  Next,  1  mg/ml  testicular
hyaluronidase  (Sigma,  St.  Louis,  MO)  in  50  mM  acetate
buffer, pH 5, was added at room temperature for 30 min. This
was  followed  by  several  washes  in  PBS.  Blocking  was
achieved using 2% BSA (BSA) in PBS at room temperature
for 1 h followed by an overnight incubation at 4 °C with
primary antibodies diluted in PBS containing 0.1% BSA and
0.01% Tween-20. A rabbit polyclonal antibody against type
XVIII collagen (QH48.18, “anti-all”) which recognizes all
three isoforms of type XVIII collagen [23] was used at a
dilution  of  1:300.  Rabbit  anti-human  type  IV  collagen
polyclonal  antibody  (Rockland,  Gilbertsville,  PA),  an
antibody against type IV collagen, was diluted 1:400 before
it was used as a basement membrane marker. After several
rinses  in  PBS,  sections  were  incubated  for  1  h  at  room
temperature with 1:300 Cy3-conjugated goat anti-rabbit IgG
secondary antibody (Jackson Laboratory, Bar Harbor, ME).
After  several  rinses  in  PBS,  sections  were  mounted  in  a
mixture of 10% 1.0 M Tris-HCl, pH 9.0 and 90% glycerol and
analyzed using a laser scanning confocal microscope (Zeiss
510META; Carl Zeiss AG, Oberkochen, Germany).
The distribution patterns and levels of expression of types
IV and XVIII collagens were analyzed using pseudocolor
images made with the thermo lookup table in the Confocal
Assistant 4.02 freeware program. This tool utilizes gray-scale
pixel values to generate pseudocolor images that allow the
discrimination  of  small  differences  in  the  level  of
immunofluorescence.
Molecular  modeling:  Human  endostatin  structure  (1BNL)
was  obtained  from  the  Protein  Data  Bank.  the  p.A1381T
change was created and analyzed using GRASP [24] and
Insight-II/Discover  software  (Molecular  Simulations  Inc.,
San Diego, CA).
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endostatin  domain  was  cloned  into  the  pET-15b  vector
(Novagen, Madison, WI). p.A1381T endostatin was produced
by PCR-based site directed mutagenesis.
Endostatin production and purification were based on a
procedure  published  elsewhere  [25].  Briefly,  recombinant
human endostatin expression in E. coli was induced using
1 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) for 3
h. Cells were isolated by centrifugation and lysed by freeze
thaw  cycle  in  GUMCAC-0-buffer,  which  contained  6  M
guanidine-HCl, 0.5 M NaCl, and 20 mM Tris-HCl, pH 7.9.
This was followed by sonication in the presence of 15 mM β-
mercaptoethanol.  Lysate  was  loaded  onto  a  ProBond™
column (Invitrogen, Carlsbad, CA) that had been previously
equilibrated with URMCAC-0 buffer, which contained 8 M
urea, 0.5 NaCl, and 20 mM Tris-HCl, pH 7.9. Endostatin was
eluted  with  a  gradient  concentration  of  imidazole  (0  to
500 mM) and dialyzed against 4 M urea, 0.1 M NaCl, 1 mM
reduced glutathione, 0.1 mM oxidized glutathione, 20 mM
Tris-HCl pH 7.9 (16 h at 4 °C). This was followed by a dialysis
against 1 M urea, 0.1 M NaCl, 0.1 mM reduced glutathione,
0.01 mM oxidized glutathione, 20 mM Tris-HCl pH 7.9 (6 h
at 4 °C), and a final dialysis step against PBS pH 6.9 (16 h at
4 °C). Human endostatin was then loaded onto a HiTrap-SP
column  (Amersham  Biosciences,  Uppsala,  Sweden)  and
eluted using a NaCl gradient (0 to 1.5 M) in PBS pH 6.9.
Buffer was exchanged by dialysis against 0.1 M NaCl and
20 mM Tris-HCl (pH 7.4) for 16 h at 4 °C.
Binding  assays:  Surface  plasmon  resonance  (SPR)  assays
were performed with a BIAcore® 3000 instrument (Biacore
AB,  Uppsala,  Sweden).  Extracellular  matrix  proteins,  the
laminin-1-nidogen-1  complex,  perlecan,  and  fibulin  were
immobilized on CM5 sensor chips (Biacore AB) as described
previously  [26].  Mouse  laminin-1-nidogen-1  complex  and
mouse perlecan were prepared from the mouse Engelbreth-
Holm-Swarm  tumor  [27].  The  recombinant  microfibrillar
component fibulin-1 was prepared following the procedure
published  by  Sasaki  et  al.  [28].  Binding  assays  were
performed in triplicates in 0.02 M Tris-HCl, 0.11 M NaCl
containing 0.05% P-20 surfactant (Biacore AB) at a flow rate
of 20 μl/min. The association phase was monitored for 3 min,
and the dissociation curve was recorded for 10 min. The bulk
effects were subtracted using the reference control surfaces.
The chips were regenerated by treatment with 1 M NaCl for
30 s. For the calculation of kinetics constants, the sensorgrams
at concentrations of 0, 10, 50, 200, and 400 nM were fitted
globally  to  the  1:1  Langmuir  model  with  BIAevaluation
software version 3.1.
ELISA assays were based on a procedure used by Rehn
et al. [25]. Laminin, type IV collagen, nidogen-1, fibulin-1,
and 10 µg/ml heparin-BSA were coated onto the surface of
microtiter wells at 4 °C overnight. All the other steps were
performed at room temperature. The wells were blocked with
5% nonfat milk in 0.05 M Tris-HCl, pH 7.4, 0.11 M NaCl,
2 mM CaCl2, 1 mM MgCl2 (TBS-Ca/Mg) for 1 h and then
washed with 0.05% Tween-20 in TBS-Ca/Mg, and incubated
for 3 h with endostatin as a soluble ligand diluted in 5% nonfat
milk  TBS-Ca/Mg.  After  thoroughly  washing,  the  samples
were incubated for 1 h with the antibody HES.6 against the
human endostatin domain [29] diluted in TBS-Ca/Mg-5%
milk, followed by washing with 0.05% Tween-20 in TBS-Ca/
Mg, and incubation with the secondary antibody conjugated
with  horseradish  peroxidase.  Endostatin  bound  to  the
immobilized  proteins  was  detected  by  adding  5-
aminosalicylic acid (Sigma) in the presence of 0.01% H2O2.
Detection was performed at 490 nm.
RESULTS
Identification of new mutations in COL18A1 leading to KS:
Mutation screening of the COL18A1 gene was performed in
five  KS  patients,  who  were  from  four  unrelated  families
(KS14–17). All the patients presented with congenital high
myopia and occipital encephalocele, typical KS phenotypic
characteristics. Three of the families are Brazilian (KS14,
KS16, and KS17) and one is North American (KS15).
We identified four mutations not previously described:
one insertion, two out-of-frame deletions in exons coding the
C-terminal region of the protein, and a splice site mutation.
All of these possibly lead to premature stop codons (Table 1).
The mutation that occurs at the acceptor splice site of intron
7,  c.929–2A>G,  involves  a  highly  conserved  base  and  is
predicted  to  disrupt  splicing  according  to  computational
analysis (NetGene2 version 2.4 [30]; NNSPLICE version 0.9
[31]). We have detected a mutation in only one of the alleles
in  families  KS14  and  KS15,  and  these  patients  may  be
compound heterozygotes. Even though the KS16 patient was
initially identified as a homozygous carrier of the mutation c.
3514_3515delCT,  we  found  only  her  mother  harbors  this
mutation. Paternity was confirmed with the analysis of five
microsatellite  markers  (D22S944,  S1623,  S1638,  S1648,
S1709). This patient also appeared homozygous for another
mutation in this exon (c.3570G>A), which is present in the
mother in heterozygosity but it is not present in the father, who
carries only the G allele of this SNP. Therefore, we concluded
that the father carries a deletion of at least exon 41 and the
patient  is  actually  hemizygous  for  the  c.3514_3515delCT
mutation and is a compound heterozygote for mutations in the
COL18A1 gene.
p.A1381T mutation leads to a weaker binding affinity to some
of  the  ECM  proteins:  To  better  understand  if  the  rare
p.A1381T endostatin mutation has the potential to disrupt its
function, we performed ELISA and SPR assays to evaluate
the fragment's ability to bind to other ECM proteins. Our
molecular  modeling  analysis  of  the  p.A1381T  endostatin
suggested that it was possible to accommodate the threonine
side chain in this position (Figure 1). ELISA assays showed
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803the  binding  properties  of  the  p.A1381T  endostatin  to  be
similar to the wild type endostatin, without any significant
differences between them. SPR experiments showed that the
p.A1381T  mutation  leads  to  a  somewhat  weaker  binding
affinity to some of the ECM proteins that were tested (Figure
2; Table 2). The differences between wild type and mutant
endostatin binding to laminin-1-nidogen-1 complex and to
fibulin-1 were small but significant (p=0.0017 and p=0.0011,
respectively). Perlecan binding was weak for both p.A1381T
and  wild  type  endostatins  and  the  difference  was  not
significant.
Skin  biopsies  from  KS  patients  do  not  show  COL18A1
expression: Null mutations that affect all type XVIII collagen
isoforms must lead to complete lack of the protein. To confirm
the  absence  of  type  XVIII  collagen  and  to  evaluate  the
possibility  of  distinguishing  KS  patients  from  normal
individuals by the analysis of type XVIII collagen in skin
biopsies,  we  performed  fluorescent  immunohistochemical
staining for type XVIII collagen in skin biopsies from two KS
individuals  carrying  the  previously  described  nonsense
mutation c.3277C>T. We observed a complete lack of type
XVIII collagen expression in the tissue sections, while control
samples displayed high levels of staining in the epithelial and
endothelial  basement  membranes  (Figure  3).  The  lack  of
expression of type XVIII collagen was especially evident in
pseudocolor, thermo images in which even minor amounts of
immunofluorescently  labeled  material  can  be  visualized.
Although  another  basement  membrane  protein,  type  IV
collagen, showed a similar distribution pattern in both control
and KS groups, its immunostaining intensity in KS samples
was noticeably lower (Figure 3).
To understand the cause of KS in individuals carrying the
change p.A1381T we also performed immunohistochemistry
from skin biopsies of two patients. Surprisingly, they also
showed lack of type XVIII collagen staining (Figure 3).
DISCUSSION
KS is thought to be a rare condition: only 42 patients from 15
unrelated  families  have  been  described  [2,4,5,16-18,20,
32-36]. Among these families, only 12 different COL18A1
mutations have been identified [3-5,15-17]. Although some
clustering has been observed in exon 41, there is heterogeneity
of mutation site distribution. Here we describe four unrelated
families harboring five different mutations (Table 1); all of
the patients are compound heterozygotes. KS16 represents an
unusual case, where the chromosome inherited from the father
has an undetermined deletion in COL18A1 that includes exon
41. This mechanism may elucidate cases already reported
where COL18A1 mutations were not detected [4]. Sequencing
the 43 exons of this gene is laborious for small study centers
to confirm the KS diagnosis, so the identification of biases in
mutation distribution could help in the molecular diagnosis.
Mutations identified so far indicate that exons 30 through 42
of COL18A1 are more frequently mutated, as 5 (83.3%) out
of 6 mutations here identified were located in these exons, as
well as 9 (64.3%) out of 14 previously identified mutations.
Interestingly,  5  (26.3%)  out  of  19  mutations  previously
identified are located in exon 41, pointing to this exon as the
most frequently affected. For this reason, we suggest that
TABLE 1. MUTATIONS IDENTIFIED IN KS PATIENTS.
Patient Mutation Region
Affected
Isoforms
Description of
mutation
KS1 c.12–2A>T (homozygous) Intron 1 Short isoform [3]
KS3 c.2969–2978delCAGGGCCCCC (maternal) Exon 36 All isoforms [4]
c.3514–3515delCT (paternal) Exon 41
KS4 c.1238–1239insA (maternal) Exon 10 All isoforms [4]
c.3514–3513delCT (paternal) Exon 41
KS5 c.3514–3515delCT (maternal) Exon 41 All isoforms [4]
c.2105delT (paternal) Exon 23
KS8 c.12–2A>T (homozygous) Intron 1 Short isoform [4]
KS9 c.3277C>T (homozygous) Exon 40 All isoforms [4]
KS10 c.2416C>T (homozygous) Exon 18 All isoforms [5], [17]
KS11 c.3769G>A (p.D1437N *) (maternal) Exon 42 All isoforms [15]
c.2823_2824insC (paternal) Exon 35
KS12 c.3601G>A (p.A1381T *) (homozygous) Exon 41 All isoforms [18]
KS13 c.3544+3A>C (homozygous) Intron 36 All isoforms [16]
KS14 c.2673_2674insC (heterozygous) Exon 33 All isoforms Novel mutation
KS15 c.2824_2831delGGCCCCCC (heterozygous) Exon 35 All isoforms Novel mutation
KS16 c.3514–3515delCT (maternal) Exon 41 All isoforms Novel mutation
exon 41 deleted (paternal) Novel mutation
KS17 c.2673_2674insC (maternal) Exon 33 All isoforms Novel mutation
c.929–2A>G (paternal) Intron 7 Novel mutation
List of published COL18A1 mutations identified in Knobloch syndrome patients and the exon numbers of the mutation sites.
Asterisk represents position based on the NC11–493 isoform (AF018081.1).
Molecular Vision 2009; 15:801-809 <http://www.molvis.org/molvis/v15/a82> © 2009 Molecular Vision
804Figure 1. Molecular modeling of wild type and p.A1381T endostatins. Analysis of the electrostatic surface of wild type (A) and p.A1381T
(B) endostatins. Areas shown in red represent a negative potential while the blue areas are positive. The position 48 of the endostatin domain
(Protein Data Bank entry 1BNL) corresponds to the position 1381 of the NC11–493 isoform (GenBank AF018081.1).
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805mutation screening in KS patients should start with these
exons. It is possible that KS is less rare, and the spectrum of
clinical variability is wider than predicted.
To find an additional way to detect type XVIII collagen
disruption in KS patients and gain a deeper understanding of
the KS etiology, we performed protein measurements in situ
and characterization of a mutation with an unknown effect in
vitro.  We  evaluated  for  the  first  time  the
immunohistochemical presence of type XVIII collagen in KS
patients. We have analyzed the distribution pattern of type
XVIII  collagen  in  skin  biopsies  of  four  KS  patients:  two
siblings  with  the  known  pathogenic  nonsense  mutation  c.
3277C>T and two other siblings with the missense endostatin
mutation c.3601G>A (p.A1381T). As expected for carriers of
null mutations, we were unable to detect type XVIII collagen
in any of the tested KS patients, including those with typical
KS clinical features that harbor the mutation p.A1381T, of
uncertain effect, confirming that the primary molecular defect
is in collagen XVIII. Interestingly, the KS samples also show
a lower expression level of type IV collagen when compared
with the control samples. Since endostatin/collagen XVIII
binds to several ECM components [12-14], it is possible that
Figure  2.  SPR  sensorgrams  of
endostatin  interactions  with  ECM
components. Endostatin variants (wild
type, mutant p.A1381T) were diluted to
a concentration series in 0.02 M Tris-
HCl,  0.11  M  NaCl  containing  0.05%
P-20, and then injected into the sensor
chips  immobilized  with  laminin-1-
nidogen-1  complex  (A=wt,
B=p.A1381T),  fibulin  (C=wt,
D=p.A1381T),  and  perlecan  (E=wt,
F=p.A1381T) at 25 °C with a flow rate
of  20  μl/min.  Sensorgrams  show
binding  of  various  concentrations  of
endostatin to the coated sensor surfaces.
The association curves were monitored
for 3 min, and the dissociation phases
were recorded for 10 min but presented
for 5 min. All the kinetics studies were
performed three times independently at
concentrations  of  0–400  nM,  and  the
data were analyzed with BIAevaluation
software  version  3.1  using  the  1:1
Langmuir binding model.
TABLE 2. BINDING AFFINITIES (KD) OF WILD TYPE AND MUTANT ENDOSTATINS TO ECM COMPONENTS
Sample Laminin-1-nidogen-1 complex Fibulin Perlecan
Wild type 3.48±0.24 nM 3.10±0.39 nM 5.53±1.53 nM
p.A1381T 6.17±0.27 nM 6.95±0.25 nM 5.19±0.92 nM
The kinetics constants were obtained by fitting the sensorgrams to the 1:1 Langmuir model.
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organization  and  stability  of  the  ECM,  especially  in  the
basement membrane where it is normally expressed.
We  also  tested  the  p.A1381T  endostatin  for  binding
affinity  to  a  selection  of  ECM  proteins.  Even  though  the
molecular modeling of the protein did not predict a significant
modification, p.A1381T has a weaker affinity to some of the
tested  ECM  components  when  compared  with  wild-type
endostatin. Indeed, Stahl et al. (2005) [19] used a recombinant
human  p.A1381T  endostatin  in  a  mammalian  expression
system and suggested that this change leads to a reduced
folding efficiency. They based this suggestion on the residue
position  and  the  observed  40%  reduction  in  p.A1381T
endostatin  production.  Considering  that  KS  is  probably
caused by a complete disruption of at least the isoform NC11–
303, the current data does not allow us to conclude that the
p.A1381T  residue  change  is  sufficient  to  lead  to  the  KS
phenotype  or  is  pathogenic,  but  this  hypothesis  seems
unlikely.  Although  in  silico  analysis  indicates  that  the  c.
3601G>A change does not create new splice sites (data not
shown),  we  cannot  exclude  the  possibility  that  it  affects
splicing in vivo and leads to creation of a premature stop
codon, since no type XVIII collagen was detected in the skin
biopsies of these patients. It is also possible that the KS in this
family is caused by a yet to be detected mutation or larger
deletion in COL18A1.
We have previously shown that endostatin serum levels
measured by an ELISA assay were lower in KS patients as
compared  with  controls  [4].  Although  we  were  able  to
discriminate patients and controls through this method, we
raised the hypothesis that the antibody used in the assay is
cross-reactive. This is evidenced by the positive endostatin
levels in KS patients that are carriers of null mutations, which
should lead to a complete or nearly complete lack of type
XVIII collagen. The immunohistochemistry results confirm
our prediction that null mutations in the COL18A1 gene lead
Figure 3. Immunofluorescent localization of type XVIII collagen in KS and control skin samples. Differential interference contrast (DIC)
images (A, F, K) show that the epithelial and connective tissues obtained from skin biopsies were intact and well preserved after being prepared
using cryofixation and cryosubstitution techniques. Immunolocalization analyses of KS patients carrying the p.A1381T change (B, C) and
the nonsense mutation c.3277C>T (NC11–493 isoform position p.G1273X, GenBank AF018081.1; G, H) were negative for expression of
collagen XVIII as compared to controls (L, M). Pseudocolor, thermo images showed that collagen XVIII expression was present in control
samples (M) but undetectable in KS samples (C, H). Although the distribution pattern of type IV collagen was similar in both control (N,
O), and KS (D, E, I, J) groups, the immunostaining intensity was noticeably lower in KS samples. The thermo color bar to the right of panel
E indicates immunofluorescence staining intensity: red, higher levels; blue/black, lower levels. Arrows point to basement membrane, and
arrowheads mark blood vessels. Scale bars equal 100 μm.
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807to  a  severe  depletion  of  the  protein.  Therefore,
immunohistochemical assessment of type XVIII collagen for
diagnosing  KS  may  be  more  precise  than  endostatin
measurements  through  ELISA  assays.  The  mutation
screening of COL18A1 gene is still expensive and laborious,
and the effect of some detected mutations may be uncertain,
as is the case for the endostatin p.A1381T change. Even when
a  possible  pathogenic  mutation  is  found,  the
immunohistochemical analysis of skin biopsies can be an
important tool to confirm the diagnosis. Finally, we show for
the first time that it is possible to diagnose KS through the
direct detection of the protein. In turn, this could allow the
screening  of  a  larger  number  of  patients  with  a  possible
diagnosis  of  KS  and  could  help  in  understanding  the
phenotypic spectrum of this syndrome.
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